Experimental models of high-risk bowel anastomosis in rats: A systematic review

Table 9 Immunosuppression models of high-risk anastomosis

Ref.	Year	Immunosuppression method	Sample size	Intervention	Test	Sampling day
Dinc et al[134]	2002	Methylprednizolone	80	GM-CSF	BPR ex situ, HP, histology (as per Ehrlich et al[25])	3
Colak et al[135]	2003	Dexamethasone	24	Trapidil	BPR ex situ, HP, histology (as per Ehrlich et al[25]), NOx, MDA	7
Sakallioglu et al[136]	2004	Dexamethasone	60	eGF	BPR ex situ, bursting site, HP, histology	7
Inglin et al[137]	2008	MMF	63	IGF-I	BPR ex situ, histology, Ki-67	2/4/6
Netta et al[138]	2014	Methylprednizolone	50	SCFA	BPR ex situ, CRP, IL-6, TNF-a	4
Karakaya et al[139]	2021	Everolimus	60	AdMSC	Macroscopic (as per Houston and Rotstein[140]), BPR ex situ, HP, histology	4/7

MMF: Mycophenolate mofetil; GM-CSF: Granulocyte-macrophage colony stimulation factors; eGF: Epidermal growth factor; IGF-I: Insulin-like growth factor; SCFA: Short chain fatty acids; AdMSC: Adipose tissue derived mesenchymal stem cells; BPR: Bursting pressure; HP: Hydroxyproline; NOx: Nitric oxide; MDA: Malondialdehyde; IL: Interleukin; TNF-a: Tumor necrosis factor-alpha.